They discuss the spotlight that has been put upon respiratory disease amid the COVID-19 pandemic, challenges faced in respiratory clinical trials, the crucial role data can play, and the focus that needs to be put upon treating lung disease to bring down mortality rates. Listen to the entire 25 minute discussion here. Highlights below:
Tell me about your background
Susan: "I did my PhD at Johns Hopkins and there I discovered the lung and all its complexity. I focused on using imaging--primarily CT--to measure the lung with great precision, both structurally and functionally; a change in lung structure leads to a change in function. With imaging you have this great degree of precision in which you can measure and find disease, differentially diagnose disease, guide therapeutics, and measure response at a level of precision far greater than what was and is available with conventional methods."
How big is the issue of lung disease?
How can retrospective data help pharma companies?